Shire raise its $30B Baxalta bid? It’s going to need some details first

Carly Helfand

Earlier this week, CEO Ludwig Hantson called 's $ 30 billion bid for his company a "lowball" offer, urging shareholders instead to look to Baxalta's standalone growth prospects. But before raises its proposal, it needs more on just what those are.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS